Literature DB >> 9234385

Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung.

M Kodate1, T Kasai, H Hashimoto, K Yasumoto, Y Iwata, H Manabe.   

Abstract

The expression of matrix metalloproteinase-2 (MMP-2; 72 kDa type IV collagenase/gelatinase A) and MMP-9 (92 kDa type IV collagenase/gelatinase B) was immunohistochemically investigated in 79 T1 adenocarcinomas of the lung using non-commercial polyclonal anti-MMP-2 and -9 antibodies. Thirty-two (41%) and 22 (28%) among the 79 cases were positive in the tumor cells for MMP-2 and -9, respectively. The incidences of MMP-2 and -9 immunoreactivities were higher (64 and 45%, respectively) in poorly differentiated tumors than in well differentiated tumors (36 and 25%, respectively), and lower in bronchioloalveolar carcinoma (22 and 10%, respectively) compared with other subtypes of adenocarcinoma. The prognosis for patients with MMP-2 and/or -9 positive immunoreactivities was significantly poorer than for those with a MMP-negative tumor (P < 0.05). The degree of collagenization was divided into four grades, and tumors with a small to abundant amount of collagen (grade 2 and grade 3 fibrosis) had a higher incidence of immunoreactivity to both types of MMP. It is estimated that these expressions might be responsible for tumor invasion, metastasis, and for grade 2 and grade 3 fibrosis in T1 adenocarcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234385     DOI: 10.1111/j.1440-1827.1997.tb04525.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  26 in total

Review 1.  Impact of smoking status on the biological behavior of lung cancer.

Authors:  Ichiro Yoshino; Yoshihiko Maehara
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

2.  A biological staging model for operable non-small cell lung cancer.

Authors:  G Cox; J L Jones; A Andi; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

3.  Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.

Authors:  Jasti S Rao; Christopher Gondi; Chandramu Chetty; Subramanyam Chittivelu; Pushpa A Joseph; Sajani S Lakka
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

4.  MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.

Authors:  Chandramu Chetty; Sajani S Lakka; Praveen Bhoopathi; Jasti S Rao
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

5.  Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis.

Authors:  Jiying Wang; Yong Cai
Journal:  Tumour Biol       Date:  2012-06-21

6.  Effects of RNAi-mediated matrix metalloproteinase-2 gene silencing on the invasiveness and adhesion of esophageal carcinoma cells, KYSE150.

Authors:  Yu-Guang Shen; Yi-Jun Xu; Zhen-Liang Shi; Hong-Li Han; Da-Qiang Sun; Xun Zhang
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

7.  Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma.

Authors:  Mumtaz V Rojiani; Janeen Alidina; Nicole Esposito; Amyn M Rojiani
Journal:  Int J Clin Exp Pathol       Date:  2010-10-16

8.  Solitary lung tumors and their spontaneous metastasis in athymic nude mice orthotopically implanted with human non-small cell lung cancer.

Authors:  T Yamaura; K Murakami; Y Doki; S Sugiyama; T Misaki; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

9.  Comparative expression of matrix metalloproteinases in low-grade mucoepidermoid carcinoma and typical lung cancer.

Authors:  Jiang Fan; Feng-Ying Wu; Lei Wang; Ge-Ning Jiang; Wen Gao
Journal:  Oncol Lett       Date:  2011-08-18       Impact factor: 2.967

10.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.